# US 5,350,687 A · Antibodies which bind to novel lymphokine related peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,350,687 A
- Document ID: US5350687A
- Status: Granted
- Kind: A
- Application number: 07/617,485
- Filed: 1990-11-21
- Granted: 1994-09-27
- Earliest claimed: 1986-10-03
- Assignees: Ciba-Geigy Corporation
- Inventors: Karel G. Odink; Roger Clerc; Nico Cerletti; Josef Bruggen; Lajos Tarcsay; Clemens Sorg; Walter Wiesendanger
- Web page: https://patentgrep.com/patent/US5350687A

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N 2830/55: from bacteria
- C12N 2830/702: yeast
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and hybrid vectors coding for said polypeptides, hosts transformed with such a hybrid vector, monoclonal and polyclonal antibodies to said polypeptides , and diagnostic methods for inflammatory conditions and cystic fibrosis.

## Claims

### Claim 1

A monoclonal antibody which specifically binds to human macrophage inhibition factor related peptide MRP-14 of the formula (II) ##STR14## wherein Z.sub.2 is hydrogen, acyl or an optionally acylated peptide residue of 1 to 5 amino acids and wherein said antibody does not crossreact with human macrophage inhibition factor related peptide MRP-8 of the formula (I) ##STR15## wherein Z.sub.1 is hydrogen, acyl or the amino acid residue methionine, or a derivative of said antibody which retains the binding pattern of the parent antibody and is selected from the group consisting of antibody fragments, radioactively labelled antibodies, and conjugates of said antibody with enzymes, biotin, avidin, fluorescent markers, chemiluminescent markers and paramagnetic particles.

### Claim 2 (depends on 1)

A monoclonal antibody according to claim 1 designated CNCM I-688 or CNCM I-687 or a derivative of said monoclonal antibody, wherein said derivative is selected from the group consisting of antibody fragments, radioactively labelled antibodies, and conjugated antibodies.

### Claim 3 (depends on 2)

A monoclonal antibody derivative according to claim 2 which is a conjugate with biotin.

### Claim 4 (depends on 1)

A hybridoma cell line, characterized in that it secrets monoclonal antibodies according to claim 1.

### Claim 5 (depends on 4)

A hybridoma cell line according to claim 4 with the designation CNCM I-688 or CNCM I-687.